Press Releases Toleranzia AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 11:23:24 2024-05-23 am EDT			5-day change	1st Jan Change
0.596 ^SEK	+0.68%		-2.61%	+39.25%

May. 20	Toleranzia AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 23	Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Notice of Annual General Meeting in Toleranzia AB (publ)	May. 20	AQ
Toleranzia AB: Interim report first quarter 2024	May. 20	AQ
Toleranzia AB: Annual report for the financial year 2023	Apr. 30	AQ
Toleranzia AB receives loan commitment of SEK 20 million	Apr. 24	AQ
Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program	Mar. 18	AQ
Toleranzia AB – Year-End Report 2023	Feb. 23	AQ
Toleranzia successfully completes GLP toxicology study of TOL2	Jan. 15	AQ
Toleranzia AB starts production of finished drug product for clinical studies	Dec. 21	AQ
Toleranzia AB presents Nomination Committee	Dec. 15	AQ
Toleranzia reports positive feedback from meeting with the Danish Medicines Agency	Dec. 06	AQ
Toleranzia AB: Interim report third quarter 2023	23-10-27	AQ
Toleranzia appoints Thomas Pålsson as new Chief Financial Officer	23-10-16	AQ
Toleranzia starts toxicology study of its lead drug candidate TOL2	23-09-26	AQ
Toleranzia announces outcome in rights issue	23-09-15	AQ
Toleranzia publishes prospectus in connection with rights issue of units	23-08-28	AQ
Toleranzia AB: Interim report second quarter 2023	23-08-25	AQ
Toleranzia establishes a freeze-dried formulation of the TOL2 drug product	23-08-24	AQ
Toleranzia runs GMP manufacturing of drug candidate TOL2 for clinical study	23-08-21	AQ
Toleranzia carries out a rights issue of units of approximately SEK 55 million	23-08-18	AQ
Announcement from the 2023 Annual General Meeting of Toleranzia AB (publ)	23-06-07	AQ

No results for this search